Adenomyosis: Genomic Mechanisms and Biological Response

N/AWithdrawnNCT03428854

University of Texas Southwestern Medical Center

Overview

Examination of genomic and biologic responses to LNG-IUS in patients with adenomyosis.

Study Type

OBSERVATIONAL

Conditions

Adenomyosis Abnormal Uterine Bleeding

Interventions

LNG-IUSDRUG

Levnorgestrel containing IUD

Eligibility

Sex: FEMALEMin age: 18 YearsMax age: 60 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Abnormal bleeding in the presence of Adenomyosis as demonstrated by MRI Exclusion Criteria: * Other causes of abnormal bleeding such as fibroids, endometrial polyps, malignancy * Presence of endometriosis

Outcomes

Primary Outcomes

Menstrual blood loss

Pictorial blood loss assessment chart

Time frame: 12 months

Secondary Outcomes

Quality of Life

SF-12

Time frame: 12 months

Pain

Visual analog scale

Time frame: 12 months

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.